Recent Finacing
Recent Raise
PYC Therapeutics develops RNA-based therapies for inherited retinal diseases, advancing three candidates including lead program VP-001 targeting retinitis pigmentosa type 11 (RP11).
Focus Areas
Total Raised
Funding round
See the team members at PYC Therapeutics.
